Anamirta Cocculus Whole Datura Stramonium Ferula A
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Anamirta Cocculus Whole Datura Stramonium Ferula A
- Multi-Ingredient Herbal/Mineral Complex: No Repurposing Prediction Available
Multi-Ingredient Herbal/Mineral Complex: No Repurposing Prediction Available
One-Sentence Summary
This candidate is a nine-ingredient complex product combining herbal, botanical, and mineral substances (including Datura stramonium, Hyoscyamus niger, silver nitrate, and valerian), with no regulatory registration in Taiwan and no matching DrugBank profile. The TxGNN model returned no predicted indications for this candidate, as the complex multi-ingredient composition cannot be mapped to a single drug node in the knowledge graph. As a result, no evidence-based repurposing assessment is possible at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Unknown — no registered indications on record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A (below L5: model returned no output) |
| Taiwan Market Status | Not Marketed (未上市) |
| Number of Licenses | 0 |
| Recommended Decision | Hold |
Why No Prediction Is Available
This submission contains nine distinct active ingredients, each from different pharmacological origins:
| Ingredient | Known Pharmacological Class |
|---|---|
| Anamirta cocculus (whole) | Homeopathic — GABA-A antagonist (picrotoxin), used for vertigo/motion sickness |
| Datura stramonium | Anticholinergic alkaloids (atropine, scopolamine) |
| Ferula assa-foetida resin | Antispasmodic, traditional carminative |
| Hyoscyamus niger | Anticholinergic (hyoscine/scopolamine source) |
| Oat bran | Dietary fiber, lipid-lowering effect |
| Paeonia officinalis root | Anti-inflammatory, traditional sedative |
| Silver nitrate | Antiseptic, escharotic agent |
| Strychnos ignatii seed | CNS stimulant (strychnine, brucine) |
| Valeriana officinalis (whole) | Sedative, anxiolytic (GABAergic activity) |
TxGNN operates on a single-drug node mapped via DrugBank ID. A multi-ingredient preparation of this complexity — spanning homeopathic botanicals, alkaloid plants, a heavy metal salt, and a dietary fiber — cannot be resolved to any individual DrugBank entry. The DrugBank query returned one result but no DrugBank ID was assigned, confirming the mapping failed.
Additionally, several ingredients (e.g., Strychnos ignatii containing strychnine, Datura stramonium containing atropine-class alkaloids) carry significant toxicity and narrow therapeutic index concerns that would ordinarily require dedicated safety data before any repurposing evaluation proceeds.
Clinical Trial Evidence
Currently no related clinical trials registered for this multi-ingredient combination.
Literature Evidence
Currently no related literature available for this combination as a unified drug entity.
Taiwan Market Information
This product has 0 registered licenses with Taiwan FDA. It is not approved or marketed in Taiwan.
Safety Considerations
Please refer to individual ingredient package inserts and monographs for safety information.
Several ingredients in this complex carry intrinsic toxicity concerns that warrant attention even without formal safety data on file:
- Datura stramonium and Hyoscyamus niger: Source plants for atropine, hyoscine, and scopolamine. Anticholinergic toxidrome risk (tachycardia, mydriasis, urinary retention, CNS effects).
- Strychnos ignatii seed: Contains strychnine — a convulsant with a very narrow margin between therapeutic and toxic dose.
- Silver nitrate: Caustic and potentially cytotoxic at higher concentrations; risk of argyria with systemic exposure.
- Anamirta cocculus: Contains picrotoxin, a GABA-A receptor antagonist; convulsant in overdose.
These ingredients present compounding risks that are not addressed by available data in this Evidence Pack.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate cannot be evaluated through the standard TxGNN repurposing pipeline because the multi-ingredient composition does not resolve to a mappable single-drug node, and the pipeline returned zero predicted indications. Several individual components carry significant safety concerns that have not been characterized for this combination.
To proceed, the following is needed:
- Clarify product identity: Determine whether this is a homeopathic preparation, a traditional medicine compound, or an investigational combination; obtain the product’s approved INN or brand name if available.
- Disaggregate for analysis: If repurposing assessment is desired, evaluate each pharmacologically active ingredient separately (particularly Datura stramonium alkaloids and Valeriana officinalis) through individual TxGNN queries.
- Resolve DrugBank mapping: A DrugBank query returned 1 result but no ID was assigned — retrieve and confirm the matched entry.
- Conduct safety review: Before any further evaluation, compile toxicity data for the highest-risk ingredients (strychnine, atropine-class alkaloids, silver nitrate).
- Confirm regulatory intent: Verify whether Taiwan TFDA registration is being sought, and under which drug category (conventional, herbal, homeopathic).
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.